Heme Oxygenase-1 Ameliorates Dextran Sulfate Sodium-induced Acute Murine Colitis by Regulating Th17/Treg Cell Balance
Overview
Affiliations
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a group of autoimmune diseases characterized by nonspecific inflammation in the gastrointestinal tract. Recent investigations suggest that activation of Th17 cells and/or deficiency of regulatory T cells (Treg) is involved in the pathogenesis of IBD. Heme oxygenase (HO)-1 is a protein with a wide range of anti-inflammatory and immune regulatory function, which exerts significantly protective roles in various T cell-mediated diseases. In this study, we aim to explore the immunological regulation of HO-1 in the dextran sulfate sodium-induced model of experimental murine colitis. BALB/c mice were administered 4% dextran sulfate sodium orally; some mice were intraperitoneally pretreated with HO-1 inducer hemin or HO-1 inhibitor stannum protoporphyrin IX. The results show that hemin enhances the colonic expression of HO-1 and significantly ameliorates the symptoms of colitis with improved histological changes, accompanied by a decreased proportion of Th17 cells and increased number of Tregs in mesenteric lymph node and spleen. Moreover, induction of HO-1 down-regulates retinoic acid-related orphan receptor γt expression and IL-17A levels, while promoting Treg-related forkhead box p3 (Foxp3) expression and IL-10 levels in colon. Further study in vitro revealed that up-regulated HO-1 switched the naive T cells to Tregs when cultured under a Th17-inducing environment, which involved in IL-6R blockade. Therefore, HO-1 may exhibit anti-inflammatory activity in the murine model of acute experimental colitis via regulating the balance between Th17 and Treg cells, thus providing a possible novel therapeutic target in IBD.
Wang Y, Ji X, Wang X, Sun M, Li C, Wu D J Inflamm Res. 2025; 18():1-15.
PMID: 39802511 PMC: 11717655. DOI: 10.2147/JIR.S485007.
Heme catabolism and heme oxygenase-1-expressing myeloid cells in pathophysiology.
Consonni F, Incerti M, Bertolotti M, Ballerini G, Garlatti V, Sica A Front Immunol. 2024; 15:1433113.
PMID: 39611159 PMC: 11604077. DOI: 10.3389/fimmu.2024.1433113.
Yang H, Wang Z, Li L, Wang X, Wei X, Gou S J Nanobiotechnology. 2024; 22(1):613.
PMID: 39385176 PMC: 11465824. DOI: 10.1186/s12951-024-02861-2.
The Pharmacological Effect of Hemin in Inflammatory-Related Diseases: A Systematic Review.
Estarreja J, Caldeira G, Silva I, Mendes P, Mateus V Biomedicines. 2024; 12(4).
PMID: 38672251 PMC: 11048114. DOI: 10.3390/biomedicines12040898.
Barbian M, Owens J, Naudin C, Denning P, Patel R, Jones R Gut Microbes. 2024; 16(1):2337317.
PMID: 38619316 PMC: 11020553. DOI: 10.1080/19490976.2024.2337317.